TheStreet upgraded shares of Electromed Inc. (NYSEMKT:ELMD) from a hold rating to a buy rating in a research report report published on Friday.

Separately, Zacks Investment Research upgraded Electromed from a sell rating to a hold rating in a research report on Thursday, May 26th.

Electromed (NYSEMKT:ELMD) opened at 4.57 on Friday. The company’s 50-day moving average price is $4.73 and its 200-day moving average price is $4.40. The firm has a market capitalization of $37.55 million, a price-to-earnings ratio of 16.93 and a beta of 0.89. Electromed has a 12-month low of $1.55 and a 12-month high of $6.26.

Electromed (NYSEMKT:ELMD) last released its quarterly earnings data on Tuesday, September 6th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by $0.01. The firm earned $5.70 million during the quarter. Equities analysts expect that Electromed will post $0.19 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in shares of Electromed during the first quarter valued at about $401,000. Bridgeway Capital Management Inc. raised its position in shares of Electromed by 800.0% in the second quarter. Bridgeway Capital Management Inc. now owns 90,000 shares of the company’s stock valued at $347,000 after buying an additional 80,000 shares during the period. Vanguard Group Inc. raised its position in shares of Electromed by 12.3% in the second quarter. Vanguard Group Inc. now owns 81,929 shares of the company’s stock valued at $316,000 after buying an additional 8,997 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Electromed by 121.3% in the second quarter. Dimensional Fund Advisors LP now owns 81,724 shares of the company’s stock valued at $315,000 after buying an additional 44,795 shares during the period. Finally, Barclays PLC raised its position in shares of Electromed by 66.4% in the second quarter. Barclays PLC now owns 48,600 shares of the company’s stock valued at $187,000 after buying an additional 19,400 shares during the period.

About Electromed

Electromed, Inc, is a pharmaceutical company. The Company manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System (SmartVest System) includes its newest generation SmartVest SQL and previous generation SV2100 and related products, to patients with compromised pulmonary function.

Receive News & Ratings for Electromed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.